141 related articles for article (PubMed ID: 8823333)
1. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
Creemers GJ; Gerrits CJ; Schellens JH; Planting AS; van der Burg ME; van Beurden VM; de Boer-Dennert M; Harteveld M; Loos W; Hudson I; Stoter G; Verweij J
J Clin Oncol; 1996 Sep; 14(9):2540-5. PubMed ID: 8823333
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
Burris HA; Awada A; Kuhn JG; Eckardt JR; Cobb PW; Rinaldi DA; Fields S; Smith L; Von Hoff DD
Anticancer Drugs; 1994 Aug; 5(4):394-402. PubMed ID: 7949242
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
[TBL] [Abstract][Full Text] [Related]
5. Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group.
Creemers GJ; Wanders J; Gamucci T; Vallentin S; Dirix LY; Schöffski P; Hudson I; Verweij J
Ann Oncol; 1995 Oct; 6(8):844-6. PubMed ID: 8589027
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
van Warmerdam LJ; ten Bokkel Huinink WW; Rodenhuis S; Koier I; Davies BE; Rosing H; Maes RA; Beijnen JH
J Clin Oncol; 1995 Jul; 13(7):1768-76. PubMed ID: 7602366
[TBL] [Abstract][Full Text] [Related]
7. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
Wall JG; Burris HA; Von Hoff DD; Rodriguez G; Kneuper-Hall R; Shaffer D; O'Rourke T; Brown T; Weiss G; Clark G
Anticancer Drugs; 1992 Aug; 3(4):337-45. PubMed ID: 1330081
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
9. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
Creemers GJ; Bolis G; Gore M; Scarfone G; Lacave AJ; Guastalla JP; Despax R; Favalli G; Kreinberg R; Van Belle S; Hudson I; Verweij J; Ten Bokkel Huinink WW
J Clin Oncol; 1996 Dec; 14(12):3056-61. PubMed ID: 8955650
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
Herben VM; ten Bokkel Huinink WW; Schot ME; Hudson I; Beijnen JH
Anticancer Drugs; 1998 Jun; 9(5):411-8. PubMed ID: 9660538
[TBL] [Abstract][Full Text] [Related]
11. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
12. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
[TBL] [Abstract][Full Text] [Related]
13. Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.
Stevenson JP; DeMaria D; Sludden J; Kaye SB; Paz-Ares L; Grochow LB; McDonald A; Selinger K; Wissel P; O'Dwyer PJ; Twelves C
Ann Oncol; 1999 Mar; 10(3):339-44. PubMed ID: 10355580
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
van Warmerdam LJ; Creemers GJ; Rodenhuis S; Rosing H; de Boer-Dennert M; Schellens JH; ten Bokkel Huinink WW; Davies BE; Maes RA; Verweij J; Beijnen JH
Cancer Chemother Pharmacol; 1996; 38(3):254-60. PubMed ID: 8646800
[TBL] [Abstract][Full Text] [Related]
15. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.
Pazdur R; Diaz-Canton E; Ballard WP; Bradof JE; Graham S; Arbuck SG; Abbruzzese JL; Winn R
J Clin Oncol; 1997 Aug; 15(8):2905-9. PubMed ID: 9256134
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
Siu LL; Oza AM; Eisenhauer EA; Firby PS; Thiessen JJ; Michael M; Wainman N; Manzo J; Feld R; Goldberg RA; Moore MJ
J Clin Oncol; 1998 Mar; 16(3):1122-30. PubMed ID: 9508199
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
[TBL] [Abstract][Full Text] [Related]
19. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
